| Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript |
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2025 Earnings Call May 8, 2025 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Jon Skinner – CFO Paul LaViolette – CEO and Co-Chairman of the Board Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences First Quarter 2025 Financial Results Conference Call. At this time all lines are in listen-only mode. |
seekingalpha.com |
2025-05-11 03:02:17 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a. |
businesswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and. |
businesswire.com |
2025-04-25 20:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717. |
businesswire.com |
2025-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its Nanosecond PFA technology will be featured in several presentations and a live case transmission featuring the nsPFA 360° catheter mapped with the CARTO™ 3 Mapping System from Johnson & Johnson MedTech at the Heart Rhythm Society (HRS) 2025 Annual Meeting, being held April 24. |
businesswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript |
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of the Board of Directors Jon Skinner - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Louella, and I will be your conference operator today. |
seekingalpha.com |
2025-03-27 21:46:11 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the t. |
businesswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 24th Annual Needham Virtual Health Care Conference. Pulse Biosciences' Management is scheduled to present on Thursday, April 10, 2025, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentation. |
businesswire.com |
2025-03-26 18:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by. |
businesswire.com |
2025-03-07 10:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming TD Cowen 45th Annual Health Care Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 5, 2025, at 10:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of. |
businesswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its nanosecond PFA Percutaneous Electrode System will be featured in a clinical science session and a video session at the North American Society for Interventional Thyroidology Annual Meeting, being held January 31 through February 1, 2025 in Washington D.C. “To obtain our initial FDA 510(k). |
businesswire.com |
2025-01-30 10:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° catheter mapped with the Abbott Ensite X 3D Mapping System at the 30th Annual AF Symposium 2025 meeting, being held January 16-18 in Boston, Massachusetts. “Since joining the Company's. |
businesswire.com |
2025-01-13 09:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Pulse Biosciences' Management is scheduled to present on Wednesday, January 15, 2025, at 3:45 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations. |
businesswire.com |
2025-01-03 11:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences, Inc. Announces Planned Redemption of Warrants |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company's stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of its. |
businesswire.com |
2024-12-23 18:30:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Co. |
businesswire.com |
2024-12-19 10:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. The preliminary data demonstrate. |
businesswire.com |
2024-10-31 16:25:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript |
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Officer Mike Koffler - Vice President, Finance Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-10-30 23:42:08 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with com. |
businesswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Bi. |
businesswire.com |
2024-10-30 18:02:00 |
Czytaj oryginał (ang.) |
| PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024 |
Pulse Biosciences (NASDAQ: PLSE ) just reported results for the second quarter of 2024. Pulse Biosciences reported earnings per share of -20 cents. |
investorplace.com |
2024-08-23 01:52:46 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript |
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffler - VP of Finance Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-12 22:50:26 |
Czytaj oryginał (ang.) |
| Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences |
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced plans to participate in two upcoming investor conferences. 9th Annual Needham MedTech & Diagnostics 1x1 Conference, virtual participation. Management will host 1x1 meetings on Tuesday, August 13, 2024. There will be no formal presentation. Canaccord Genuity Annual Growth Co. |
businesswire.com |
2024-08-01 20:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE) |
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The investigation seeks to determine whether Pulse Bioscience's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-08-01 15:44:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences, Inc. Announces Commencement of Rights Offering |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below). The subscription rights will expire and have no value if they are not exercised prior to 5:0. |
businesswire.com |
2024-06-04 12:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19. “We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case. |
businesswire.com |
2024-05-16 12:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Enhances Executive Leadership Team |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”), today announced enhancements to its executive leadership team to support its next pivotal phase of growth. Proven atrial fibrillation medical technology leader Burke T. Barrett has been appointed President and Chief Executive Officer effective immediately. Concurrently, the Company announced the appointm. |
businesswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript |
Pulse Biosciences Inc (NASDAQ:PLSE ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Philip Taylor - Principal, Gilmartin Group LLC Kevin Danahy - President & CEO Michael Koffler - VP, Finance Mitchell Levinson - Chief Strategy Officer Darrin Uecker - CTO & Director Robert Duggan - Executive Chairman Conference Call Participants Anthony Petrone - Mizuho Securities Robert Lovgren - Medical Hope Production Operator Greetings, and welcome to the Pulse Biosciences First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-11 17:29:05 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent Business Highlights CellFX nsPFA Percutaneous Electrode March 2024, received FDA 510(k) clearance for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures. CellFX nsPFA Car. |
businesswire.com |
2024-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company's Board of Directors has set the record date for the Company's previously announced rights offering (the “Rights Offering”), which will be available to all holders of record of the Company's common stock, par value $0.001 per share (the “Common Stock”), a. |
businesswire.com |
2024-05-02 12:00:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for d. |
businesswire.com |
2024-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript |
Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-28 22:52:08 |
Czytaj oryginał (ang.) |
| Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023. Recent Business Highlights CellFX nsPFA Percutaneous Electrode (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system) Received U.S. FDA 510(k) clearance for us. |
businesswire.com |
2024-03-28 18:12:00 |
Czytaj oryginał (ang.) |